
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4458735/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. Journal of Crohn's and Colitis, 2020, 14, 4-22.	1.3	741
2	ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment. Journal of Crohn's and Colitis, 2020, 14, 155-168.	1.3	478
3	Incidence and Patterns of COVID-19 Among Inflammatory Bowel Disease Patients From the Nancy and Milan Cohorts. Clinical Gastroenterology and Hepatology, 2020, 18, 2134-2135.	4.4	101
4	Accuracy of Humanitas Ultrasound Criteria in Assessing Disease Activity and Severity in Ulcerative Colitis: A Prospective Study. Journal of Crohn's and Colitis, 2018, 12, 1385-1391.	1.3	85
5	Comparative Accuracy of Bowel Ultrasound Versus Magnetic Resonance Enterography in Combination With Colonoscopy in Assessing Crohn's Disease and Guiding Clinical Decision-making. Journal of Crohn's and Colitis, 2018, 12, 1280-1287.	1.3	79
6	Metagenomic analysis of intestinal mucosa revealed a specific eukaryotic gut virome signature in early-diagnosed inflammatory bowel disease. Gut Microbes, 2019, 10, 149-158.	9.8	70
7	Inflammatory Bowel Disease Care in the COVID-19 Pandemic Era: The Humanitas, Milan, Experience. Journal of Crohn's and Colitis, 2020, 14, 1330-1333.	1.3	69
8	Targeting S1P in Inflammatory Bowel Disease: New Avenues for Modulating Intestinal Leukocyte Migration. Journal of Crohn's and Colitis, 2018, 12, S678-S686.	1.3	64
9	Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials. Expert Opinion on Investigational Drugs, 2018, 27, 595-599.	4.1	57
10	Transperineal Perineal Ultrasound Versus Magnetic Resonance Imaging In the Assessment of Perianal Crohn's Disease. Inflammatory Bowel Diseases, 2013, 19, 2737-2743.	1.9	55
11	Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2018, 24, 601-606.	1.9	50
12	Thiopurine treatment in inflammatory bowel disease: Response predictors, safety, and withdrawal in follow-up. Journal of Crohn's and Colitis, 2012, 6, 588-596.	1.3	48
13	MFSD2A Promotes Endothelial Generation of Inflammation-Resolving Lipid Mediators and Reduces ColitisÂinÂMice. Gastroenterology, 2017, 153, 1363-1377.e6.	1.3	48
14	Point-of-Care Ultrasound in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2021, 15, 143-151.	1.3	46
15	Advanced endoscopic techniques in the assessment of inflammatory bowel disease: new technology, new era. Gut, 2019, 68, 562-572.	12.1	42
16	Maintaining the Quality Standards of Care for Inflammatory Bowel Disease Patients During the COVID-19 Pandemic. Clinical Gastroenterology and Hepatology, 2020, 18, 1882-1883.	4.4	40
17	Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study. Clinical Gastroenterology and Hepatology, 2016, 14, 1426-1432.e1.	4.4	39
18	Perianal disease is associated with psychiatric co-morbidity in Crohn's disease in remission. International Journal of Colorectal Disease, 2014, 29, 1285-1290.	2.2	36

FEDERICA FURFARO

#	Article	IF	CITATIONS
19	Glucose intolerance and diabetes mellitus in ulcerative colitis: Pathogenetic and therapeutic implications. World Journal of Gastroenterology, 2014, 20, 3507.	3.3	35
20	Disease patterns in late-onset ulcerative colitis: Results from the IG-IBD "AGED study― Digestive and Liver Disease, 2017, 49, 17-23.	0.9	35
21	Illness Perception in Inflammatory Bowel Disease Patients is Different Between Patients With Active Disease or in Remission: A Prospective Cohort Study. Journal of Crohn's and Colitis, 2019, 13, 417-423.	1.3	35
22	Milan ultrasound criteria are accurate in assessing disease activity in ulcerative colitis: external validation. United European Gastroenterology Journal, 2021, 9, 438-442.	3.8	34
23	Efficacy of tumour necrosis factor antagonists in stricturing Crohn's disease: A tertiary center real-life experience. Digestive and Liver Disease, 2017, 49, 872-877.	0.9	33
24	Can IL-23 be a good target for ulcerative colitis?. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2018, 32-33, 95-102.	2.4	31
25	Sexual and reproductive issues and inflammatory bowel disease: a neglected topic in men. European Journal of Gastroenterology and Hepatology, 2018, 30, 316-322.	1.6	30
26	Predictive Value of Bowel Ultrasound in Crohn's Disease: A 12-Month Prospective Study. Clinical Gastroenterology and Hepatology, 2022, 20, e723-e740.	4.4	30
27	Psychological Characteristics of Inflammatory Bowel Disease Patients: A Comparison Between Active and Nonactive Patients. Inflammatory Bowel Diseases, 2019, 25, 1399-1407.	1.9	27
28	Long-term outcome of inflammatory bowel diseases with cytomegalovirus colitis. European Journal of Gastroenterology and Hepatology, 2014, 26, 1146-1151.	1.6	26
29	The safety of biological pharmacotherapy for the treatment of ulcerative colitis. Expert Opinion on Drug Safety, 2017, 16, 437-443.	2.4	24
30	Modulation of sphingosine-1-phosphate in ulcerative colitis. Expert Opinion on Biological Therapy, 2020, 20, 413-420.	3.1	24
31	Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology. Digestive and Liver Disease, 2022, 54, 440-451.	0.9	22
32	Bowel ultrasound score is accurate in assessing response to therapy in patients with Crohn's disease. Alimentary Pharmacology and Therapeutics, 2022, 55, 446-454.	3.7	21
33	Biosimilars of adalimumab: the upcoming challenge in IBD. Expert Opinion on Biological Therapy, 2019, 19, 1023-1030.	3.1	20
34	Histological Scores in Patients with Inflammatory Bowel Diseases: The State of the Art. Journal of Clinical Medicine, 2022, 11, 939.	2.4	20
35	The impact of symptoms, irritable bowel syndrome pattern and diagnostic investigations on the diagnostic delay of Crohn's disease: A prospective study. Digestive and Liver Disease, 2015, 47, 646-651.	0.9	19
36	Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study. Digestive and Liver Disease, 2019, 51, 510-515.	0.9	18

#	Article	lF	CITATIONS
37	Validation of the Red Flags Index for Early Diagnosis of Crohn's Disease: A Prospective Observational IG-IBD Study Among General Practitioners. Journal of Crohn's and Colitis, 2020, 14, 1777-1779.	1.3	18
38	JAK inhibitors: Novel developments in management of ulcerative colitis. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2018, 32-33, 89-93.	2.4	17
39	IL-23 Blockade for Crohn s disease: next generation of anti-cytokine therapy. Expert Review of Clinical Immunology, 2017, 13, 457-467.	3.0	16
40	SFED recommendations for IBD endoscopy during COVID-19 pandemic: Italian and French experience. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 507-516.	17.8	16
41	Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting. Digestion, 2017, 96, 166-172.	2.3	15
42	PK, PD, and interactions: the new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD. Expert Review of Gastroenterology and Hepatology, 2020, 14, 797-806.	3.0	15
43	Positioning ustekinumab in moderate-to-severe ulcerative colitis: new kid on the block. Expert Opinion on Biological Therapy, 2020, 20, 421-427.	3.1	15
44	Ulcerative colitis: current pharmacotherapy and future directions. Expert Opinion on Pharmacotherapy, 2014, 15, 1659-1670.	1.8	14
45	Late-onset Crohn's disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammatory Bowel Disease â€~AGED' study. European Journal of Gastroenterology and Hepatology, 2019, 31, 1361-1369.	1.6	14
46	Targeting the gut layers in Crohn's disease: mucosal or transmural healing?. Expert Review of Gastroenterology and Hepatology, 2020, 14, 775-787.	3.0	13
47	Viral infections in inflammatory bowel disease: Tips and tricks for correct management. World Journal of Gastroenterology, 2021, 27, 4276-4297.	3.3	13
48	Overview of Biological Therapy in Ulcerative Colitis: Current and Future Directions. Journal of Gastrointestinal and Liver Diseases, 2020, 24, 203-213.	0.9	13
49	TL1A: A New Potential Target in the Treatment of Inflammatory Bowel Disease. Current Drug Targets, 2021, 22, 760-769.	2.1	11
50	Rediscovering histology: what is new in endoscopy for inflammatory bowel disease?. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110056.	3.2	11
51	Patient's profiling for therapeutic management of inflammatory bowel disease: a tailored approach. Expert Review of Gastroenterology and Hepatology, 2020, 14, 765-773.	3.0	11
52	Predictive value of Milan ultrasound criteria in ulcerative colitis: A prospective observational cohort study. United European Gastroenterology Journal, 2022, 10, 190-197.	3.8	11
53	Unrevealed Depression Involves Dysfunctional Coping Strategies in Crohn's Disease Patients in Clinical Remission. Gastroenterology Research and Practice, 2016, 2016, 1-7.	1.5	9
54	Splanchnic Hemodynamics and Intestinal Vascularity in Crohn's Disease: An InÂVivo Evaluation Using Doppler and Contrast-Enhanced Ultrasound and Biochemical Parameters. Ultrasound in Medicine and Biology, 2016, 42, 150-158.	1.5	9

#	Article	IF	CITATIONS
55	Interleukin-23 Blockers: Born to be First-line Biologic Agents in Inflammatory Bowel Disease?. Current Pharmaceutical Design, 2019, 25, 25-31.	1.9	9
56	The Importance of Disease Prevalence in Assessing the Diagnostic Value of a Test: Endoscopic Markers in Celiac Disease. Digestion, 2013, 87, 254-261.	2.3	8
57	Validation of the â€~United Registries for Clinical Assessment and Research' [UR-CARE], a European Online Registry for Clinical Care and Research in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2018, 12, 532-537.	1.3	8
58	Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that?. Current Pharmaceutical Design, 2019, 25, 7-12.	1.9	8
59	Reproducibility of the electronic chromoendoscopy PICaSSO score (Paddington International Virtual) Tj ETQq1 1 multicenter international study (with video). Gastrointestinal Endoscopy, 2022, 96, 73-83.	0.784314 1.0	rgBT /Overic 8
60	Letter: immunogenicity of infliximab originator vs. <scp>CT</scp> â€₱13 in <scp>IBD</scp> patients. Alimentary Pharmacology and Therapeutics, 2017, 46, 903-905.	3.7	7
61	Application of Ultrasound Elastography for Assessing Intestinal Fibrosis in Inflammatory Bowel Disease: Fiction or Reality?. Current Drug Targets, 2021, 22, 347-355.	2.1	7
62	Emerging therapeutic targets and strategies in Crohn's disease. Expert Review of Gastroenterology and Hepatology, 2016, 10, 735-744.	3.0	6
63	Inflammatory bowel disease course in liver transplant versus non-liver transplant patients for primary sclerosing cholangitis: LIVIBD, an IG-IBD study. Digestive and Liver Disease, 2021, 53, 712-716.	0.9	6
64	Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study. Biomedicines, 2022, 10, 843.	3.2	6
65	Early Biological Therapy in Operated Crohn's Disease Patients Is Associated With a Lower Rate of Endoscopic Recurrence and Improved Long-term Outcomes: A Single-center Experience. Inflammatory Bowel Diseases, 2023, 29, 539-547.	1.9	6
66	Gut and mesenteric lymph node involvement in pediatric patients infected with human immunodeficiency virus. HIV/AIDS - Research and Palliative Care, 2014, 6, 69.	0.8	5
67	Bowel Ultrasound in Inflammatory Bowel Disease: How Far in the Grayscale?. Life, 2021, 11, 649.	2.4	5
68	PF-00547659 for the treatment of Crohn's disease and ulcerative colitis. Expert Opinion on Investigational Drugs, 2018, 27, 623-629.	4.1	4
69	Detection and management of early stage inflammatory bowel disease: an update for clinicians. Expert Review of Gastroenterology and Hepatology, 2019, 13, 547-555.	3.0	4
70	Endoscopy after surgery in inflammatory bowel disease: Crohn's disease recurrence and pouch surveillance. Expert Review of Gastroenterology and Hepatology, 2020, 14, 829-841.	3.0	4
71	Absence of COVID-19 Infection in Patients Accessing IBD Unit at Humanitas, Milan: Implications for Postlockdown Measures. American Journal of Gastroenterology, 2020, 115, 1719-1721.	0.4	4
72	Epidemiological features and disease-related concerns of a large cohort of Italian patients with active Crohn's disease. Digestive and Liver Disease, 2019, 51, 804-811.	0.9	3

#	Article	IF	CITATIONS
73	Prevention of Postoperative Recurrence in CD: Tailoring Treatment to Patient Profile. Current Drug Targets, 2019, 20, 1327-1338.	2.1	3
74	Artificial Endoscopy and Inflammatory Bowel Disease: Welcome to the Future. Journal of Clinical Medicine, 2022, 11, 569.	2.4	3
75	Cross-Sectional Imaging Instead of Colonoscopy in Inflammatory Bowel Diseases: Lights and Shadows. Journal of Clinical Medicine, 2022, 11, 353.	2.4	3
76	Evolution and New Horizons of Endoscopy in Inflammatory Bowel Diseases. Journal of Clinical Medicine, 2022, 11, 872.	2.4	3
77	Improving quality of care in endoscopy of inflammatory bowel disease: can we do better?. Expert Review of Gastroenterology and Hepatology, 2020, 14, 819-828.	3.0	2
78	JAK inhibitors in crohn's disease: ready to go?. Expert Opinion on Investigational Drugs, 2022, 31, 145-161.	4.1	2
79	Assessment of the disease extension in children and adolescents with IBD: Comparison of bowel ultrasound and magnetic resonance enterography. Digestive and Liver Disease, 2014, 46, e120.	0.9	1
80	Intestinal gas and liver steatosis: a casual association? A prospective multicentre assessment. Liver International, 2017, 37, 141-147.	3.9	1
81	Psychological Functioning of Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2019, 25, e112-e112.	1.9	1
82	New Paradigms to Help Decisions in Treatment Choice: Head to Head Trial of Biological Therapies in Inflammatory Bowel Diseases. Current Drug Targets, 2021, 22, 370-378.	2.1	1
83	Comparison of two methods for the in-vivo diagnosis of Helicobacter pylori infection using a tablet of 13C-urea. Minerva Gastroenterology, 2017, 63, 319-326.	0.5	1
84	Colorectal Cancer Surveillance in Patients with Inflammatory Bowel Diseases: Chromoendoscopy or Non-Chromoendoscopy, That Is the Question. Journal of Clinical Medicine, 2022, 11, 509.	2.4	1
85	Response Evaluation and Safety of Thiopurines in the Treatment of Inflammatory Bowel Diseases (IBD). Gastroenterology, 2011, 140, S-280-S-281.	1.3	0
86	19 Infliximab Discontinuation Is Associated With a Higher Risk for Relapse in Patients With Ulcerative Colitis in Remission: A Multinational Collaborative Retrospective Study. Gastroenterology, 2016, 150, S6.	1.3	0
87	Mo1987 Accuracy of a New Fujiifilm Blue Light Prototype in Predicting the Histology of Subcentimetric Polyps. Gastrointestinal Endoscopy, 2016, 83, AB485.	1.0	0
88	Rapid Detection of Anti-Infliximab Antibodies in Inflammatory Bowel Disease Patients Treated with the Reference Biologic or the Biosimilar CT-P13: Performance Comparison with Elisa. Gastroenterology, 2017, 152, S384.	1.3	0
89	Switching from Infliximab Originator to CT-P13 is not Related to Increased Immunogenicity in IBD Patients: A Prospective Case-Control Study. Gastroenterology, 2017, 152, S384.	1.3	0
90	Antibodies to Infliximab in Patients Treated with Either the Reference Biologic or the Biosimilar CT-P13 Show Identical Reactivity Towards Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease. Gastroenterology, 2017, 152, S386.	1.3	0

#	Article	IF	CITATIONS
91	Comparative Accuracy of us Versus MRI and Colonoscopy in Assessing Disease Activity and Complications and Influencing the Decision-Making Process in Crohn's Disease. Gastroenterology, 2017, 152, S66.	1.3	ο
92	Stimulation of CYP450-Mediated Ω-3 Docosahexaenoic Acid (DHA) Metabolism via MFSD2A as a Novel Therapy for Inflammatory Bowel Disease. Gastroenterology, 2017, 152, S188.	1.3	0
93	Illness Perception in IBD Patients: A Prospective Study. Gastroenterology, 2017, 152, S800.	1.3	О
94	Psychological Challenges for Patients With Inflammatory Bowel Disease During the COVID-19 Pandemic. Psychosomatic Medicine, 2021, 83, 397-398.	2.0	0